Rare cases of clotting that have been seen with two Covid-19 vaccines have put the spotlight on an uncommon reaction that occurs when the body unleashes its immune firepower against blood platelets.

The pause in the rollout of Johnson & Johnson’s Covid-19 vaccine marks another setback for the world’s inoculation campaign, just as it was picking up speed in Europe and other regions where immunizations have lagged.

For the past year the pandemic has brought a halt to in-person inspections of many pharmaceutical manufacturing facilities around the world. With a backlog of more than 1,000 audits to clear, the U.S. Food and Drug Administration is facing pressure to embrace something it’s long eschewed: virtual inspections of foreign drug plants.

President Joe Biden’s trade chief met with drugmakers and with groups seeking a waiver for sections of the World Trade Organization’s intellectual-property rules to improve vaccine access for poorer nations.

Australian Trade Minister Dan Tehan will travel for face-to-face talks with ministerial counterparts in Germany, France and Brussels from Thursday, after the European Union restricted exports of Covid-19 vaccines.

U.S. health officials urged a pause on the use of Johnson & Johnson’s Covid-19 vaccine due to dangerous blood-clotting to give them time to educate doctors on how to treat the exceedingly rare disorder and to “look in all the nooks and crannies” for other cases.